AI Terminal
STRATEC SE
Regulatory Filings • Nov 28, 2018
416_rns_2018-11-28_4c45367e-f50e-4ab6-8613-df521031e5b0.html
Regulatory Filings
Open in ViewerOpens in native device viewer
News Details
Corporate | 28 November 2018 13:58
STRATEC completes transformation of legal form into a European Company
DGAP-News: STRATEC SE / Key word(s): Miscellaneous
28.11.2018 / 13:58
The issuer is solely responsible for the content of this announcement.
STRATEC completes transformation of legal form into a European Company
Birkenfeld, November 28, 2018
STRATEC Biomedical AG has completed its conversion into a European Company (Societas Europaea, SE), known as STRATEC SE. The new legal form is now effective following its entry in the commercial register of the Mannheim municipal court.
“The new legal form highlights the international orientation and open corporate culture that the STRATEC Group already has and also creates ideal structures for future growth,” said Chairman of the Board of Management Marcus Wolfinger.
STRATEC SE will continue to have a dual system with a Board of Management and a Supervisory Board. STRATEC SE’s head office is still in Birkenfeld, Baden-Württemberg, Germany.
Following the submission of a resolution proposal to this effect by the Board of Management and the Supervisory Board, the Annual General Meeting had approved the transformation into an SE with a large majority on May 30, 2018. The rights of shareholders and employees are not affected by the change of legal form. The shareholders of STRATEC Biomedical AG have now automatically become shareholders of STRATEC SE. The securities identification numbers (WKN and ISIN) of STRATEC’s shares and their ticker symbols remain unchanged.
About STRATEC
STRATEC SE ( www.stratec.com ) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. Furthermore, the company offers sample preparation solutions, integrated laboratory software, and complex consumables for diagnostic and medical applications. STRATEC covers the entire value chain – from development to design and production through to quality assurance.
The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of its own patented technologies.
Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange.
Further information can be obtained from:
STRATEC SE
Jan Keppeler, Investor Relations & Corporate Communications
Gewerbestr. 37, 75217 Birkenfeld
Deutschland
Tel: +49 7082 7916-6515
Fax: +49 7082 7916-9190
28.11.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | STRATEC SE |
| Gewerbestr. 37 | |
| 75217 Birkenfeld | |
| Germany | |
| Phone: | +49 (0)7082 7916 0 |
| Fax: | +49 (0)7082 7916 999 |
| E-mail: | [email protected] |
| Internet: | www.stratec.com |
| ISIN: | DE000STRA555 |
| WKN: | STRA55 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| End of News | DGAP News Service |